Drug Profile
Remacemide
Alternative Names: PR 934423Latest Information Update: 08 Oct 2003
Price :
$50
*
At a glance
- Originator AstraZeneca R&D Charnwood
- Class Acetamides; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Glutamate receptor antagonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy; Huntington's disease; Neurological disorders; Neuropathic pain; Parkinson's disease; Stroke
Most Recent Events
- 25 Jul 2002 Discontinued - Clinical-Phase-Unknown for Neuropathic pain in USA (unspecified route)
- 25 Jul 2002 Discontinued - Phase-II for Neurological disorders in USA (unspecified route)
- 25 Jul 2002 Discontinued - Phase-II for Parkinson's disease in USA (PO)